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ARTICLE
Fine Mapping versus Replication in Whole-Genome Association
Studies
Geraldine M. Clarke, Kim W. Carter, Lyle J. Palmer, Andrew P. Morris, and Lon R. Cardon
Association replication studies have a poor track record and, even when successful, often claim association with different
markers, alleles, and phenotypes than those reported in the primary study. It is unknown whether these outcomes reflect
genuine associations or false-positive results. A greater understanding of these observations is essential for genomewide
association (GWA) studies, since they have the potential to identify multiple new associations that that will require
external validation. Theoretically, a repeat association with precisely the same variant in an independent sample is the
gold standard for replication, but testing additional variants is commonplace in replication studies. Finding different
associated SNPs within the same gene or region as that originally identified is often reported as confirmatory evidence.
Here, we compare the probability of replicating a gene or region under two commonly used marker-selection strategies:
an “exact” approach that involves only the originally significant markers and a “local” approach that involves both the
originally significant markers and others in the same region. When a region of high intermarker linkage disequilibrium
is tested to replicate an initial finding that is only weak association with disease, the local approach is a good strategy.
Otherwise, the most powerful and efficient strategy for replication involves testing only the initially identified variants.
Association with a marker other than that originally identified can occur frequently, even in the presence of real effects
in a low-powered replication study, and instances of such association increase as the number of included variants increases.
Our results provide a basis for the design and interpretation of GWA replication studies and point to the importance of
a clear distinction between fine mapping and replication after GWA.
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Genomewide association (GWA) studies are now under
way, involving hundreds of thousands of genetic markers
genotyped in thousands of individuals.1–3 The hope for
such studies is that they will identify major loci, although
the expectation is that most findings will comprise
smaller-effect variants that appear to be more likely to
occur than by chance alone, but which initially are not
exceptional enough to be unambiguously related to the
outcomes.4–6 Meta-analyses and results of initial genome-
wide studies support this pattern of effects.7–19 Thus, there
soon will be thousands of possible disease loci for which
some indicative evidence emerges from GWA studies, but
which will then require further scrutiny for validation.
Independent replication, the process by which valida-
tion of study results may be achieved, has long been the
strategy of choice to validate initial reports of genetic as-
sociation. Unfortunately, such studies are regarded as one
of the weakest aspects of human genetics, achieving a dis-
proportionately small number of successful outcomes de-
spite tens of thousands of attempts.20–22 Confusingly, even
when success is declared for replication, many of the stud-
ies show seemingly implausible patterns in which differ-
ent markers, alleles, and phenotypes are found to be as-
sociated in the initial and subsequent studies.23 In some
cases, the disease-predisposing risk allele in the primary
study is reported as the “protective” allele in the repli-
cation study.23,24 The contradictory results are then as-
cribed to undetected genetic, allelic, phenotypic, and pop-
ulation heterogeneity.25 A brief history and description of
prospects for replication studies of complex traits has been
presented recently by Chanock et al.26
In theory, an additional significant association with ex-
actly the same allele in an independent sample is the gold
standard for replication. However, this is not often the
practice of association researchers. Instead, so-called rep-
lication studies often comprise a hybrid design involving
rigorous testing of the same markers (exact replication)
plus fine mapping of additional loci in the same region.
There are several reasons why such a design might be em-
ployed. First, the indirect nature of whole-genome scans
means that other markers in an association region may
be more strongly correlated with the disease variant(s) and
thereby offer greater statistical power to detect an asso-
ciation. This possibility has motivated the development
of “gene-based” association tests that expressly allow for
marker and allelic variability in the patterns of allelic as-
sociation.27 Additional variants are also pursued in repli-
cation studies, because of their location in coding or pro-
moter regions, low levels of linkage disequilibrium (LD),
marker gaps in the initial coverage, allele-frequency hy-
potheses, external biological information, or prior as-
sumptions. This desire to include additional markers,
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Figure 1. Exact and local replication strategies. Exact strategies involve testing only those markers that exceed some significance
threshold in the primary study, whereas local replication studies involve testing additional markers on the basis of genomic information,
such as LD patterns, marker gaps, and gene locations (shown) or other prior hypotheses. In the local strategy, the markers tested may
include some loci that were not deemed “significant” in the initial study, as well as new SNPs that were not tested initially at all.
combined with the difficulties in irreproducibility of
exact replication, has led many investigators to use what
we refer to as “local” replication, whereby a subsequent
significant association observed within the same gene or
region in an independent sample is taken as confirmation
of the role of that gene or region in the etiology of the
disease of interest.23 The differences between exact and
local replication strategies are depicted in figure 1.
Note that this form of replication differs from “repli-
cation” in multistage GWA studies or in situations where
data from multiple sample resources can be combined for
greater power of initial detection (or, more commonly,
where data from a single resource is not split into sepa-
rately analyzed pieces to “save” some samples for repli-
cation).28 Such strategies focus on initial detection and are
thus hypothesis generating. Replication in the present
context is of the traditional hypothesis-testing form, used
broadly by different investigators with different samples
and study designs. These types of replication studies aim
to independently verify initial association reports and to
obtain accurate effect-size estimates, regardless of the de-
signs used in the primary study to detect the effects. The
eventual utility, robustness, and acceptance of the GWA
approach will depend in part on the correct design, exe-
cution, and interpretation of such studies. Here, we for-
mally compare the exact and local replication strategies
in the presence of a real association, to assess the perfor-
mance of each approach under different conditions and
to determine their practical utility as follow-up designs for
GWA.
Material and Methods
Study Designs
We refer to the putatively associated markers in the primary study
as the “representative” markers. The exact replication strategy
involves testing only the representative marker(s) from the orig-
inal study; the local replication strategy involves testing the rep-
resentative marker(s) plus other markers that may or may not
have been genotyped in the primary study but that are selected
because of LD patterns, candidate genes, gaps in initial coverage,
or other hypotheses of the investigator (fig. 1). For both designs,
we assume that representative markers are used to identify K
regions of interest, each of which contains one or more genuine
disease-susceptibility loci. Note that the actual disease loci are not
necessarily genotyped in either the primary or the replication
studies, but they are correlated with markers in the regions. The
replication study then involves genotyping a representative
marker and biallelic markers in each region. Markers areM 1
assumed to be in LD, measured by , with the causal alleles. If2r
, then a marker is defined to be true. We assume that m2r 1 0
( ) of the markers tested in each region are true. We declarem M
replication to be successful in a region when one or more of the
tested markers exceed the significance criteria of both the initial
and the replication studies. In all cases, we assume that the rep-
lication sample is independent of the initial sample but is drawn
from the same population and is matched with respect to pheno-
type, covariate, and ascertainment effects. Note that, under these
assumptions, the conditional probability of replication is simply
the probability of a successful association in the second test; here,
we report the joint probability of replication given the presence
of a real association.
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Analytical Probabilities for Local versus Exact Designs
We consider single-marker tests of association and define a marker
to be successful in a given study if it exceeds the significance
criteria of that study. Let , , be the event thatP (i) ip 1, … ,L1
marker i is successful in the primary study. Suppose that a region
containing a single representative marker and additionalM 1
markers is identified, and markers are genotyped as part of a
replication study. Let , , be the event that markerP (j) jp 1, … ,M2
j is successful in the replication study. Let be the event thatR(i)
a successful replication occurred at locus i—that is, that repre-
sentative marker i was successful in the initial study, and at least
one other marker in the region was successful in the replication
study. Then, a general expression for isR(i)
Pr [R(i)]p Pr [I p 1]{1Pr [S (M)p 0]} ,P (i) 21
where is thePr [S (M)p 0]p Pr [I p 0, I p 0, … ,I p 0]2 P (1) P (2) P (M)2 2 2
joint probability of no successful replication at any of the markers
in the replication study and is an indicator function that takes
the value 1 if it is true and 0 otherwise.
Given case and control allele frequencies at the causal locus,
sample sizes, and the ratio of cases to controls, the marginal prob-
ability of a single marker being successful in a standard x2 test of
association is dependent only on the intermarker LD between the
alleles at the marker and the causal locus.29 To accommodate the
testing of multiple markers, we need to consider the intermarker
LD between alleles at each pair of test markers, since the LD
relationships at one pair of markers generate constraints on the
range of LD at other correlated markers.30 A marker is defined to
be true if it has a real association with a causal locus; otherwise,
it is false. Here, we assume zero intermarker LD between any pairs
of markers in the region that include at least one false marker,
an assumption that is not expected to affect the overall replica-
tion probabilities but that simplifies calculation of probabilities
and multiple-testing corrections. Suppose that m of the M markers
in the region are true. For simplicity of notation, we arbitrarily
order the true markers as and the false markers as1, … ,m m
. Then,1, … ,M
Pr [R(i)]
M
p Pr [I p 1] 1Pr [S (m)p 0] Pr [I p 0] . (1){  }P (i) 2 P (j)1 2
jpm1
Instead of considering specific LD patterns, which vary widely
and sometimes unpredictably between chromosome regions and
samples,27 we examine the upper and lower bounds that delineate
the range of possible replication outcomes for different LD
patterns.
In regions of perfect intermarker LD between pairs of true mark-
ers , the true markers collapse to a single2(r p 1; j,k  m; j( k)j,k
locus, providing a lower bound for :Pr [R(i)]
B { Pr [R(i)]l
M
 Pr [I p 1] 1Pr [I p 0] Pr [I p 0] , (2){  }P (i) P (1) P (j)1 2 2
jpm1
where we have arbitrarily used the probability of success at marker
1 because, when for all m markers, all the true markers in2r p 1jk
the replication study must have the same probability of success.
Note that, in the case of the exact replication strategy, ,mpM
so expression (2) reduces to the probability of initially detecting
and replicating a trait association with marker 1. In cases of lo-
cal replication, we make a Bonferroni correction with ′a p
. Note that this is a theoretical lower bound de-a/K(Mm 1)
signed to elucidate general findings and is impossible to calculate
generally in this manner if given a specific region where markers
all have different allele frequencies.
In regions of no intermarker LD between pairs of true markers
( ), probabilities of success are independent,2r p 1; j,k ! m; j( kj,k
and, under the assumption of positive dependence between tests
of association at successive markers, the upper bound of
is a function of the power at each locus:Pr [R(i)]
M
B { Pr [R(i)] Pr [I p 1] 1 Pr [I p 0] .{  }u P (i) P (j)1 2
jp1
In this situation, we make a standard Bonferroni correction
( ). Note that, when , , and figure 2′a p a/KM Mp mp 1 B p Bl u
shows these exact probabilities in regions of a single represen-
tative marker as red lines. See appendix A for a discussion of the
rationale for the conditions required to achieve upper and lower
bounds of .Pr [R(i)]
“Replication” of Markers Not Detected in Initial Study
Let be the event that there is a local replication but that the
—
R(i)
representative marker is not successful in the second test. For
,M 1 1
—
Pr [R(i)]p Pr [I p 1]Pr [I p 0P (i) P (i)1 2
and at least one of I p 1, j( i] .P (j)2
Note that, by definition, when . In regions
—
Pr [R(i)]p 0 Mp 1
of no intermarker LD, the maximum probability of can be
—
R(i)
determined:
M—
Pr [R(i)] Pr [I p 1] Pr [I p 0] Pr [I p 0] .{  }P (i) P (i) P (j)2 2 2
jp1
In regions of complete intermarker LD, .
—
Pr [R(i)]p 0
Correction for Multiple Testing
For an overall type I error of a, we correct for multiple testing by
setting the Bonferroni-corrected significance rate, , as a function′a
of a nominal level, the total number of markers tested, and the
LD structure among them. All markers in the original study are
assumed to be independent; so, for an original study involving
M markers, , ensuring an overall type I error rate of a.′a p a/M
Suppose a replication study involves the examination of K in-
dependent regions. Under our parameterization of the problem,
we consider each region to be replicated independently. Thus, we
require a difference in the correction for multiple testing to be
applied within the region, compared with between regions, and
so we have assumed that each region will have its own overall
type I error rate of . Within each region, the error rate′a p a/K
is further corrected according to the effective number of inde-
pendent tests performed within this region. Hence, for region k,
consisting of independent and dependent markers,I D ′M M a pK K
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Figure 2. Theoretical probabilities of observing local replication in a region of 50 markers ( ) as a function of the commonMp 50
value of LD between the true marker and causal alleles. The number, m, of true markers is shown above the panels. The dotted green
line shows the probability of achieving a significant result at the representative marker in the original study only. The red line shows
the probability of achieving an exact replication. Since original and replicate study samples are assumed to be independent, the value
at the red line is the product of the value at the green line and the probability of achieving a significant result at the representative
marker in a replicate study when no additional markers are tested. The gray-shaded region represents the range of replication probabilities
at all possible levels of LD between marker and disease loci. The upper bound of the gray-shaded region represents the maximum
probability of replication for any given level of LD between each marker and a causal locus (X-axis), which occurs when all markers in
the region are independent. This upper bound is represented with a dashed black line to emphasize the fact that, when multiple markers
in a given region are independent, the possible value of LD between each marker and a single causal locus is constrained, and so the
upper bound cannot be attained at all levels of LD between the marker and causal loci. The lower bound of the gray-shaded region
represents the minimum probability of replication for any given level of LD between each marker and a causal locus, which occurs when
all markers in the region are independent. This lower bound can be attained for all levels of LD between the marker and causal loci.
The disease prevalence is 0.05, the GRR is 1.3, and the frequency of the high-risk allele is 0.25. In the first stage, 500,000 markers
are genotyped for 3,000 cases and 3,000 controls. In the replication study, regions are identified, and markers are genotypedKp 10
for 1,500 cases and 1,500 controls. To ensure an overall type I error rate of 0.05 in the replicate study, the Bonferroni corrected rate
is then when the true markers are dependent and is when the true markers are′ ′a p 0.05/[10# (50m 1)] a p 0.05/(10# 50)
independent. Panel D duplicates panel A to highlight the specific region for this example in which the maximum probability of replication
cannot be attained, emphasizing the implicit requirement of allelic heterogeneity (multiple disease alleles) when the between marker2r
and causal alleles is sufficiently large. For these sample parameter values, this occurs for . (See appendix A for details on2r 1 0.42
calculation of this cutoff value.)
. The upper and lower bounds of replication prob-DI MKa/K(M  1 )K
abilities are found at these extreme conditions of complete and
absent intermarker LD. Our correction is highly conservative in
regions of no intermarker LD and allows for the detailed exam-
ination of replication within a set of independent regions.
Examining Variation across Genes ATGL161 and IL23R
To provide an example, to illustrate the effect of real LD patterns,
we use data from the International HapMap Project31 to compare
the probability of local and exact replication in a simulation study
designed to mimic primary and replicate studies that aim to find
associations at markers in LD with SNP rs2241880 (minor-allele
frequency [MAF] of 0.453) in the ATG16L1 gene and SNP
rs7517847 ( ) in the IL23R gene (MIM 607562). BothMAFp 0.403
SNPs are known to be associated with Crohn disease (MIM
266600).7,32 Using genotype data from CEPH samples (Utah res-
idents with ancestry from northern and western Europe), we ran-
domly select 50 markers within 100 kb of each SNP to represent
additional markers selected for a replication study. We treat
rs2241880 and rs7517847 as causal SNPs, and, for each randomly
selected additional marker, we calculate the LD between the
marker and “causal” alleles. For each value of LD equal to 0.1,
0.2,…, 1 between the initially associated marker and the causal
alleles, we then compute the maximum probability of local rep-
lication and the probability of exact replication for 10,000 sim-
ulations. The maximum probability of local replication occurs
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Figure 3. Theoretical probabilities of observing local replication in a region of markers as a function of the common valueMp 50
of LD between true marker and causal alleles. This graph is identical to figure 2 except that, instead of all m true markers havingm 1
a common value of LD between marker and causal alleles, one of the additional markers selected is independent of all other markers
and is in perfect LD with the causal variant. See the figure 2 legend for more details on the graphs. Values for m are shown above the
panels.
when markers are independent; clearly, the markers are not in-
dependent here, and so these estimates of local replication prob-
ability are biased upward and thus present the best possible case
for local replication.
Disease prevalence, genotype relative risk (GRR), the frequency
of the high-risk allele, and all other study parameters are as de-
scribed in the figure 2 legend. Since our purpose here is to com-
pare the relative probabilities of exact and local replication, the
exact values of these study parameters do not affect our findings.
Results
Power of Replication under Exact and Local Strategies
To explore formally the different contexts of local and
exact replication, we compare the power to achieve each
under two strategies, using theoretical expectations under
the limiting conditions of complete and absent intermar-
ker LD (see the “Methods” section). The results of these
assessments elucidate several trends.
The shaded region in figure 2A–2D represents the prob-
abilities of local replication across the range of intermarker
LD as a function of the LD between the true marker and
causal alleles; the lower boundary in each panel represents
complete intermarker LD, and the upper boundary rep-
resents absent intermarker LD. The red line represents the
probability of achieving an exact replication. Notice that,
in all panels, the probability of replication at the lower
boundary is always less than the probability of exact rep-
lication, illustrating the fact that, at the extreme of com-
plete intermarker LD in a region, the local strategy cannot
improve on the exact strategy. This is because the addition
of any true markers in such a region is, of course, entirely
redundant, and the inclusion of false markers will always
reduce the probability of local replication in any region,
as a simple consequence of the resulting penalties required
to correct for multiple testing.
As intermarker LD decreases, the probability of local-
replication success with a local strategy increases. The ex-
tent to which the local strategy is beneficial is strongly
influenced by the proportion of genuinely associated
markers among those added in the replication study (we
refer to markers that are genuinely associated with the
disease loci as “true”; see the “Methods” section for our
operational definition). Figure 2A, 2B, and 2C represents
situations with 2/50, 10/50, and 50/50 true markers, re-
spectively. When very few of the new markers are true,
the exact strategy performs better than the local strategy
(fig. 2A). As the proportion of true markers increases, the
local strategy becomes increasingly effective, as can be
seen by the upper bound of the local replication strategy
exceeding the power of the exact strategy in figure 2B and
2C. This is unsurprising because the addition of new mark-
ers in a region that has many true but initially uncaptured
loci would be expected to increase power. At the same
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Figure 4. Pairwise plot for the HapMap CEU data from release 22, April 2007. The intensity of the shading is proportional to the2r
value of . A, rs2241008, at 233,848,107 bp on chromosome 2, contained within a single block of LD. B, rs7517847, at 67,454,2572r
bp on chromosome 1, between two blocks of LD.
time, however, it is increasingly penalized by the correc-
tions required for multiple testing. When many of the new
markers are not associated with the disease locus, as is the
case in 48 of the 50 markers in figure 2A, the penalty
becomes so severe that it offsets the increased power.
Examples illustrated in figure 2 assume that all true
markers tested in the replication study have a common
value of LD between the marker and causal alleles. The
best case for local replication occurs when one or more
of the additional true markers selected for the replication
study is in greater LD with the causal variant than is the
marker identified in the primary study. Figure 3 contrasts
figure 2, showing changes to the upper and lower bounds
of the probability of local replication in the extreme sit-
uation where one of the additional markers selected is
independent of all other markers and is in perfect LD with
the causal variant. The upper and lower bounds of the
probability of local replication have increased and have
converged, and, with a sufficient number of true markers,
the probability of local replication is greater than that of
exact replication at all values of LD between the remain-
ing additional marker and causal alleles. In general, the
strength and number of true markers, as well as the ratio
of true to false markers added in a local replication design,
cannot be known in advance, so it is practically impossible
to predict the optimal selection of markers in advance of
a replication study.
In a simulation of possible outcomes for replication of
associations across genes known to be associated with
Crohn disease, we considered 100-kb regions around SNPs
rs2241880 and rs7517847. rs2241880 lies in a region of
high intermarker LD; rs7517847 lies in a region of me-
dium-to-low intermarker LD, as shown in figure 4. Figure
5A shows that, when a region of high intermarker LD is
tested, as the probability of exact replication decreases,
the maximum probability of local replication improves
relative to the probability of exact replication. This is be-
cause the local strategy provides a good chance of picking
up a marker in higher LD with the causal variant than the
initially identified variant when the initial finding is weak.
Figure 5B confirms that, when a region of low intermarker
LD is tested, the exact strategy is generally optimal when
the initial finding is strongly associated with disease and
that the local strategy is increasingly dependent on ad-
ditional marker selection as the strength of the initial find-
ing decreases.
Overall, the benefits of the local strategy are most prom-
inent in the presence of allelic heterogeneity and low LD.
In regions of incomplete intermarker LD, the level of LD
between any marker and a causal locus is constrained.29
Therefore, when only a single disease locus is present in
a low-LD region, it is not possible for multiple markers to
each be highly correlated with it. The results in figure 2D
expand those of figure 2A to show that, under that par-
ticular scenario, if there is only a single disease locus, then
the upper bound of the local replication power is only
feasible when the marker-disease is less than a given2r
value (for the particular parameter values of our example,
) determined by constraints on the haplotype2r !∼ 0.42
frequencies and the values imposed by the local LD2r
patterns (appendix B). This constraint will become more
severe as the number of added markers increases, thereby
further lowering the permissible LD levels between the
marker and disease locus. Unless there is allelic hetero-
geneity, the selection of appropriate markers required to
optimize a strategy of local replication in a region of low
intermarker LD may be too challenging in practice to yield
success.
As a by-product of these considerations, it is important
to emphasize the obvious point that the power of the
initial GWA study is paramount in determining the prob-
ability of replication—that is, the probability of initially
detecting a locus and then replicating it in an independent
sample cannot exceed the power of the initial study. This
is important to recognize in the context of GWA studies
because a number of strategies aim to reduce genotyping
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Figure 5. Maximum probability of local replication as a function of the probability of exact replication in simulations designed to
mimic the outcomes of replication that attempts to find an association under the assumption that rs2241880 (A) and rs7517847 (B)
are causal SNPs. Each point corresponds to a single simulation. The solid black line is for reference only, indicating when exact and
maximum local replication probabilities are equal. See the “Methods” section for full details on simulations.
costs by minimizing the genotyping in the initial GWA
study, at the cost of the power of initial detection.27
The example illustrated in figure 2 involves a replication
study with the same type I error but with lower power
than that of the original study. This example was selected
to provide optimal visual clarification of the possible dif-
ferences between the exact and local approachs. In other
examples, the value of power and the significance thresh-
olds used in the primary and replication studies will alter
the absolute value of the results but will have no bearing
on the relative merits of replication under the exact strat-
egy versus under the local strategy.
In summary, our findings indicate that the effectiveness
of the local strategy increases with the number and
strength of true markers among the additional markers
included in the replicate study. Results suggest that, when
the original marker is strongly associated with disease—
either because there is a large effect or because it is highly
correlated with the causal variant—then an exact strategy
is the best approach. This is because, in regions of low
intermarker LD where the local strategy performs best, the
chance of finding one or more additional markers that
have a higher correlation with the causal variant than the
originally identified variant does is small, and, in regions
of high intermarker LD where there are perhaps additional
highly correlated markers, the differences between the lo-
cal and exact strategies are minimal. However, when the
original marker is only weakly associated, the local strat-
egy is likely to be a good approach in regions of high
intermarker LD, because there is good chance of picking
up at least one marker that is in greater LD with the causal
variant than is the original marker. Although it is theo-
retically possible to benefit from a local replication strat-
egy for a weakly associated initial finding in a region of
low intermarker LD, it depends critically on the selection
of true markers. If cost is an issue, then the exact approach
is generally the better strategy, because even when addi-
tional markers do improve the effectiveness of the local
strategy, the difference between the maximum probabil-
ity of local replication and that of exact replication is
marginal.
Fine-scale assessments of other markers in the region,
although perhaps justified on biological and genetic
grounds, will usually be more fruitfully pursued in samples
other than those used to validate the initial results. Fine-
scale mapping studies of the initial GWA samples may be
useful for identifying other correlated markers for subse-
quent follow-up, but it is important to recognize the po-
tential biases in initial effect-size estimates that will ac-
company such a strategy (i.e., the “winner’s curse”).33
“Replicating” Markers Other Than Those Initially Identified
Several studies have reported associations with markers
other than those initially reported, even when the initial
markers were tested among those added in the follow-up
study,28 with the differences often attributed to allelic or
genetic heterogeneity. Figure 6 shows that this event can
occur frequently without allelic heterogeneity.
At the extreme of complete intermarker LD, the prob-
ability of successful replication with some marker other
than tthe original representative locus is zero, since highly
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Figure 6. Maximum probability that a locus exceeds the significance threshold in a replication study but is different from the locus
initially identified. Each line shows results for a different number of true markers (m), as indicated, tested in a region of Mp 50
markers in the replicate study and corresponds to the probability that a single true marker is identified in the first study but not in
the second study, even though the second study has sufficient power to detect similar nearby markers. The disease prevalence, risk,
allele frequencies, sample sizes, marker designs, and type I error are as described in the figure 2 legend.
dependent markers cannot be simultaneously successful
and unsuccessful. In regions of incomplete LD and/or for
weak power in the replication study, the chances of de-
tecting an association with some locus in a region in-
creases with the number of new variants tested, at a rate
that depends on the proportion of genuinely associated
markers, whereas the probability of replicating the original
representative marker decreases slowly, as a result of the
increasingly conservative correction required. In this sit-
uation, the use of the local replication approach appears
to be useful as an extension of association discovery, al-
though not as a validation tool, since such results would
initiate the need for further validation by another
mechanism.
Discussion
We have examined two strategies commonly employed in
replication studies of genetic association: the exact strat-
egy, in which only significant loci are subsequently tested
in a replication study, and the local stategy, in which ad-
ditional variants are also included. We found that, in gen-
eral, the exact strategy is more balanced in power and
efficiency, in terms of cost and ability to replicate a max-
imum number of loci. However, it is possible to benefit
from testing additional markers, especially when a region
of high intermarker LD is tested and the initial finding is
weakly associated with disease. This might occur, for ex-
ample, when coverage in the initial GWA is poor. It is
important to note that, when the local strategy does im-
prove power, the patterns of association can often reveal
different loci than those initially identified, thus rendering
the interpretation difficult and likely requiring yet another
validation study.
A precise value for local replication probability or tighter
bounds on the range of local replication probabilities
would require accurate consideration of the LD structure
between markers and causal variants and could not be
used for general inference. The local replication strategy
also places strong demands on accurately accounting for
the dependence between multiple tests. We have used the
boundary conditions of complete or zero LD to obtain the
range of possible values in figure 2. At these boundaries,
multiple-testing corrections are straightforward. If the
multiple-testing procedure used in any specific study is
anticonservative, then local replication will inflate false-
positive rates for apparent replication, whereas, if it is con-
servative, then true replications will be missed. Permuta-
tion procedures or nonfrequentist approaches to follow-up
association validation may offer more flexibility and util-
ity to local replication; Bayesian methods are particularly
beneficial when markers are selected with prior informa-
tion based on a previously significant association or func-
tional relevance.33
For practical purposes and without loss of generality, we
have assumed that significant markers to be replicated can
be separated into regions. This is the basis for defining K
regions to be replicated and for defining local replication
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success on a region-by-region basis. If, instead, there are
multiple significant markers in a small region, then this
may serve to increase the probability of local replication
for any one of these markers, but comparisons between
exact and local strategies for a particular marker proceed
as usual. Marker density has an effect here implicitly, in
terms of the intermarker LD, which is modeled only at
the extremes for multiple markers in any given region.
Intermediate values of LD and associated marker density
are not considered explicitly. This is an appealing aspect
of the theoretical method we have devised for compari-
sons of exact and local strategies and makes it applicable
to a wide range of factors that influence the performance
of each strategy.
Many ongoing GWA studies are multistage in design. In
general, these are not as powerful as replication strategies
per se, but, instead, are used for efficient primary detection
of new loci in large samples.27 Our focus here was not on
such studies but was on the next step in the process of
disease-gene characterization: verification of the initial
GWA findings in independent samples. In this regard, our
results call for a clear distinction between fine mapping
and replication. Novel loci detected by GWA are candi-
dates for replication. Conversely, when a disease gene or
region has already been confirmed, fine-mapping studies
may help clarify the specific variants involved. The exact
strategy is clearly a replication approach, one which has
the added benefit of offering the possibility of further
combining replication data with those from the initial
GWA scan. The local strategy, however, combines both
replication and fine mapping and, in doing so, increases
ambiguity in the outcomes.
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Appendix A
Bounds for the Joint Probability Distribution of Standard
Tests of Association at Multiple Markers
An upper bound for the probability that all tests are
unsuccessful in a replicate study is given by
Pr [S (M)p 0]2
! max{Pr [I p 0],Pr [I p 0],…,Pr [I ]} .P (1) P (2) P (M)p02 2 2
Note that the upper bound occurs naturally when markers
are in complete LD, so that the tests are statistically de-
pendent, in which case
Pr [S (M)p 0]p Pr [I p 0] . (A1)2 P (1)2
Under the assumption of positive dependence between
successive tests at all M markers in the replication study,34
a lower bound is given by
Pr [S (M)p 0]2
1 Pr [I p 0]Pr [I p 0],…,Pr [I p 0] .P (1) P (2) P (M)2 2 2
If successive standard tests of association at all M mark-
ers in a replication study are independent, then the prob-
ability that all tests are unsuccessful is the product of the
marginal probabilities that each test is unsuccessful:
Pr [S (M)p 0]2
p Pr [I p 0]Pr [I p 0],…,Pr [I p 0] . (A2)P (1) P (2) P (M)2 2 2
That is, the lower bound occurs when markers are in com-
plete linkage equilibrium, so that the tests are statistically
independent.
Application of equations (A1) and (A2) to equation (1)
gives lower and upper bounds, respectively, for inPr [R(i)]
the case of positive dependence between tests of associ-
ation at successive markers. When there is no positive
dependence between tests at successive markers, a non-
zero lower bound cannot be found for the joint distri-
bution. Consideration of equation (1) indicates that, at
this extreme, the probability of local replication reduces
to the probability of success in the first test.
Appendix B
Restrictions on Intermarker LD between Two Marker Loci
as a Result of LD between the Marker and Causal Alleles
Consider three biallelic loci, labeled A, B, and C, with
major alleles A, B, and C and minor alleles a, b, and c,
respectively. Let the frequency of allele A be . Let thepA
frequency of allele B on chromosomes carrying an A (a)
allele be ( ). Then, the frequency of allele B isp pBFA BFa
, and the LD between loci A andp p p p  p (1 p )B BFA A BFa A
B can be expressed as
p (1 p )A A2 2r p (p  p ) # . (B1)AB BFA BFa p (1 p )B B
Similarly, let the frequency of allele C on chromosomes
carrying an A (a) allele be ( ). Similar results thenp pCFA CFa
hold for the frequency of allele C, , and for the LD be-pC
tween loci A and C, .2rAC
Suppose that the joint distribution between loci A and
B and that between loci A and C are identical. Specifically,
let and ; then, for example, 2p p p p p p r pBFA CFA BFA CFa AB
, , , , and2r p p p p p p p p pAC AC AB aC aB B C
2 2(p  p )BC B2r p . (B2)BC 2 2p (1 p )B B
Using the fact that the sum of the various joint distri-
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butions of alleles at the three loci must equal the appro-
priate joint distribution of alleles at any two of the loci,
we can derive the constraints
max(0,p  p ) p  p (B3)AB Ab ABC AB
and
max(0,p  p ) p  p . (B4)aB ab aBC aB
If we let and take on their maximum values—p pABC aBC
and , respectively—thenp p p :p p  p p p AB aB BC ABC aBC AB
, and, from expression (B2), it is easy to see thatp p paB B
. Hence, for any given common value of LD be-2r p 1BC
tween loci A and B and between loci A and C, the LD
between loci B and C can always take on the maximum
value 1.
From expression (B2), it can also be seen that if2r p 0BC
and only if . Since , summation of2p p p p p p  pBC B BC ABC aBC
the constraints (B3) and (B4) gives the following con-
straint on :pBC
max(0,p  p )max(0,p  p ) p  p .AB Ab aB ab BC B
Hence, if can be selected such that , where2p p ! SB B
Spmax(0,p  p )max(0,p  p )AB Ab aB ab
pmax[0,p (2p  1)]max[0,(1 p )(2p  1)] ,A BFA A BFa
then it will not be possible to have , and so2 2p p p r 1BC B BC
. There are three cases:0
(i) When and , then .p ! 0.5 p ! 0.5 Sp 0BFa BFA
(ii) When and , then .p  0.5 p  0.5 Sp 2p  1BFa BFA B
(ii) When and or when andp ! 0.5 p  0.5 p ! 0.5BFa BFA BFA
.p  0.5BFa
In cases (i) and (ii), would have to be negative in orderpB
that ; thus, is unrestricted here. Also observe that,2 2p ! S rB BC
by considering the maximum and minimum values of
and in these two cases, expression (B1) indicatesp pBFa BFA
that . In case (iii), expression (B1) in-20 r ! p /(1 p )AB A A
dicates that , and it is possible to select2r  p /(1 p )AB A A
so that . Hence, can be restricted here, and the2 2p p ! B rB B BC
restriction gets increasingly severe as ap-Fp  p FBFa BFA
proaches 1 or, equivalently, as approaches 1. Thus, if2rAB
the common value of LD between loci A and B, , or2rAB
between loci A and C, , is , then the LD2r 1 p /(1 p )AC A A
between loci B and C, , is constrained to be nonzero.2rBC
Conversely, as decreases to zero, the maximum value2rBC
of decreases to .2r p /(1 p )AB A A
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for IL23R and Crohn disease)
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